CL2018000375A1 - 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1. - Google Patents
2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.Info
- Publication number
- CL2018000375A1 CL2018000375A1 CL2018000375A CL2018000375A CL2018000375A1 CL 2018000375 A1 CL2018000375 A1 CL 2018000375A1 CL 2018000375 A CL2018000375 A CL 2018000375A CL 2018000375 A CL2018000375 A CL 2018000375A CL 2018000375 A1 CL2018000375 A1 CL 2018000375A1
- Authority
- CL
- Chile
- Prior art keywords
- tetrahydropyridines
- fluoromethyl
- fluoro
- phenyl
- amino
- Prior art date
Links
- FEEJBUWYRJKRNV-UHFFFAOYSA-N 5-fluoro-5-(fluoromethyl)-2-methyl-2-phenyl-3,4-dihydropyridin-6-amine Chemical class NC1=NC(CCC1(CF)F)(C1=CC=CC=C1)C FEEJBUWYRJKRNV-UHFFFAOYSA-N 0.000 title 1
- 229940125759 BACE1 protease inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE FÓRMULA I, PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS O COGNITIVAS. EL MÉTODO PROPORCIONA ADEMÁS LOS INTERMEDIOS PIPERIDINA-2-ONA Y PIPERIDINA-2-TIONA DE LOS COMPUESTOS DE FÓRMULA I.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500465 | 2015-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000375A1 true CL2018000375A1 (es) | 2018-07-06 |
Family
ID=56615973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000375A CL2018000375A1 (es) | 2015-08-12 | 2018-02-09 | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10011596B2 (es) |
| EP (1) | EP3334720A1 (es) |
| JP (1) | JP2018531889A (es) |
| KR (1) | KR20180033524A (es) |
| CN (1) | CN107849011A (es) |
| AR (1) | AR105668A1 (es) |
| AU (1) | AU2016305275A1 (es) |
| BR (1) | BR112017007472A2 (es) |
| CA (1) | CA2993630A1 (es) |
| CL (1) | CL2018000375A1 (es) |
| CO (1) | CO2018000798A2 (es) |
| CR (1) | CR20180077A (es) |
| DO (1) | DOP2018000040A (es) |
| EA (1) | EA201890256A1 (es) |
| EC (1) | ECSP18010535A (es) |
| HK (1) | HK1253372A1 (es) |
| IL (1) | IL257007A (es) |
| MA (1) | MA42597A (es) |
| MX (1) | MX2018001699A (es) |
| NI (1) | NI201800020A (es) |
| PE (1) | PE20181015A1 (es) |
| PH (1) | PH12018500268A1 (es) |
| RU (1) | RU2018104868A (es) |
| TN (1) | TN2018000035A1 (es) |
| TW (1) | TW201718543A (es) |
| WO (1) | WO2017025559A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| KR20190077349A (ko) | 2016-10-28 | 2019-07-03 | 하. 룬드벡 아크티에셀스카브 | 이미다조피라지논의 투여를 포함하는 병용 치료 |
| SG11201903770UA (en) | 2016-10-28 | 2019-05-30 | H Lundbeck As | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| BR112018017058A2 (pt) * | 2016-12-21 | 2019-07-02 | H Lundbeck As | 6-amino-5-fluoro-5-(fluorometil)-2,3,4,5-tetra-hidropiridin-2-il-fenil-5-(metóxi-d3)-pirazina-2-carboxamidas e derivados fluorados do mesmo como inibidores de bace1 |
| RS62551B1 (sr) | 2017-12-14 | 2021-12-31 | H Lundbeck As | Kombinovane terapije koje obuhvataju primenu 1h-pirazolo[4,3-b]piridina |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| CN117447475A (zh) | 2017-12-20 | 2024-01-26 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
| KR20210112968A (ko) | 2020-03-07 | 2021-09-15 | 장성환 | 양면 인쇄가 가능한 라벨 제조방법 |
| KR20230012296A (ko) | 2021-07-15 | 2023-01-26 | 장성환 | 양면 인쇄가 가능한 라벨 제조방법 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| PT1474395E (pt) | 2002-02-12 | 2008-01-02 | Smithkline Beecham Corp | Derivados de nicotinamida úteis como inibidores de p38 |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| SG185651A1 (en) | 2010-06-09 | 2012-12-28 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| JP2014505688A (ja) | 2011-01-12 | 2014-03-06 | ノバルティス アーゲー | オキサジン誘導体および神経障害の処置におけるその使用 |
| AU2012206561B2 (en) | 2011-01-13 | 2015-12-17 | Novartis Ag | Novel heterocyclic derivatives and their use in the treatment of neurological disorders |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| CN103608345A (zh) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
| KR20140041687A (ko) | 2011-06-07 | 2014-04-04 | 에프. 호프만-라 로슈 아게 | Bace1 및/또는 bace2 억제제로서의 할로겐-알킬-1,3-옥사진 |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| JP2015514073A (ja) | 2012-03-20 | 2015-05-18 | エラン ファーマシューティカルズ， リミテッド・ライアビリティ・カンパニー | スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用 |
| WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| MX366855B (es) | 2013-03-01 | 2019-07-26 | Amgen Inc | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. |
| TWI639607B (zh) | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Ｂａｃｅ抑制劑 |
| CR20160352A (es) * | 2014-02-19 | 2016-10-20 | H Lundbeck As | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| JO3458B1 (ar) * | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| MA40941A (fr) * | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
-
2016
- 2016-08-10 EP EP16748316.3A patent/EP3334720A1/en not_active Withdrawn
- 2016-08-10 MA MA042597A patent/MA42597A/fr unknown
- 2016-08-10 EA EA201890256A patent/EA201890256A1/ru unknown
- 2016-08-10 AR ARP160102458A patent/AR105668A1/es unknown
- 2016-08-10 MX MX2018001699A patent/MX2018001699A/es unknown
- 2016-08-10 US US15/233,463 patent/US10011596B2/en not_active Expired - Fee Related
- 2016-08-10 CN CN201680045234.5A patent/CN107849011A/zh active Pending
- 2016-08-10 HK HK18112668.6A patent/HK1253372A1/zh unknown
- 2016-08-10 CA CA2993630A patent/CA2993630A1/en not_active Abandoned
- 2016-08-10 TW TW105125417A patent/TW201718543A/zh unknown
- 2016-08-10 WO PCT/EP2016/069029 patent/WO2017025559A1/en not_active Ceased
- 2016-08-10 KR KR1020187004062A patent/KR20180033524A/ko not_active Withdrawn
- 2016-08-10 PE PE2018000231A patent/PE20181015A1/es not_active Application Discontinuation
- 2016-08-10 BR BR112017007472A patent/BR112017007472A2/pt not_active Application Discontinuation
- 2016-08-10 US US15/751,765 patent/US20180244645A1/en not_active Abandoned
- 2016-08-10 TN TNP/2018/000035A patent/TN2018000035A1/en unknown
- 2016-08-10 AU AU2016305275A patent/AU2016305275A1/en not_active Abandoned
- 2016-08-10 CR CR20180077A patent/CR20180077A/es unknown
- 2016-08-10 RU RU2018104868A patent/RU2018104868A/ru not_active Application Discontinuation
- 2016-08-10 JP JP2018506847A patent/JP2018531889A/ja active Pending
-
2018
- 2018-01-18 IL IL257007A patent/IL257007A/en unknown
- 2018-01-26 CO CONC2018/0000798A patent/CO2018000798A2/es unknown
- 2018-02-05 PH PH12018500268A patent/PH12018500268A1/en unknown
- 2018-02-06 NI NI201800020A patent/NI201800020A/es unknown
- 2018-02-08 DO DO2018000040A patent/DOP2018000040A/es unknown
- 2018-02-09 EC ECIEPI201810535A patent/ECSP18010535A/es unknown
- 2018-02-09 CL CL2018000375A patent/CL2018000375A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20180077A (es) | 2018-04-09 |
| PE20181015A1 (es) | 2018-06-26 |
| NI201800020A (es) | 2018-06-29 |
| WO2017025559A1 (en) | 2017-02-16 |
| TN2018000035A1 (en) | 2019-07-08 |
| DOP2018000040A (es) | 2018-04-30 |
| AU2016305275A1 (en) | 2018-02-08 |
| ECSP18010535A (es) | 2018-04-30 |
| TW201718543A (zh) | 2017-06-01 |
| KR20180033524A (ko) | 2018-04-03 |
| PH12018500268A1 (en) | 2018-08-13 |
| JP2018531889A (ja) | 2018-11-01 |
| IL257007A (en) | 2018-03-29 |
| AR105668A1 (es) | 2017-10-25 |
| CA2993630A1 (en) | 2017-02-16 |
| HK1253372A1 (zh) | 2019-06-14 |
| US20170044151A1 (en) | 2017-02-16 |
| CO2018000798A2 (es) | 2018-05-10 |
| US10011596B2 (en) | 2018-07-03 |
| EP3334720A1 (en) | 2018-06-20 |
| MX2018001699A (es) | 2018-05-07 |
| BR112017007472A2 (pt) | 2018-01-23 |
| US20180244645A1 (en) | 2018-08-30 |
| EA201890256A1 (ru) | 2018-06-29 |
| CN107849011A (zh) | 2018-03-27 |
| MA42597A (fr) | 2018-06-20 |
| RU2018104868A (ru) | 2019-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000375A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1. | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| BR112018011709A2 (pt) | inibidores bicíclicos de pad4 | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CO2017005959A2 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| PH12016501613A1 (en) | Pyrazines modulators of gpr6 | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| BR112017019176A2 (pt) | processos para a preparação de fluorocetolídeos | |
| BR112018006422A2 (pt) | composições e métodos para inibir beta-lactamase | |
| BR112018017058A2 (pt) | 6-amino-5-fluoro-5-(fluorometil)-2,3,4,5-tetra-hidropiridin-2-il-fenil-5-(metóxi-d3)-pirazina-2-carboxamidas e derivados fluorados do mesmo como inibidores de bace1 | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |